We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
152 hedge funds and large institutions have $991M invested in Esperion Therapeutics in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $17.8M
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
6.2% less ownership
Funds ownership: 105.68% → 99.48% (-6.2%)
9% less funds holding
Funds holding: 167 → 152 (-15)
25% less capital invested
Capital invested by funds: $1.32B → $991M (-$333M)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
Holders
152
Holders Change
-15
Holders Change %
-8.98%
% of All Funds
3.33%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
15
Increased
49
Reduced
50
Closed
30
Calls
$23.3M
Puts
$17.8M
Net Calls
+$5.52M
Net Calls Change
-$13.9M
Top Buyers
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$72.3M |
| 2 |
SIM
Spark Investment Management
New York
|
-$7.52M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$6.14M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.97M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.88M |
